Choice Detox Center, Inc. dba Nofeel
Letter data
- Company
- Choice Detox Center, Inc. dba Nofeel
- Recipient
- Mr. Kenneth Nersten | Choice Detox Center, Inc. dba Nofeel | Choice Detox Center, Inc. dba Nofeel | 552 Hamilton Street | Suite E-1 | Costa Mesa | , | CA | 92627 | United States
- Issue date
- 2018-09-11
- Posted date
- Not available
- FDA office
- Center for Food Safety and Applied Nutrition
- Subject
- Not available
- Product
- Drugs
- CMS ID
- 543456
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Choice Detox Center, Inc. dba Nofeel
MARCS-CMS 543456 —
September 11, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Product:
Drugs
Recipient:
Recipient Name
Mr. Kenneth Nersten
Choice Detox Center, Inc. dba Nofeel
Choice Detox Center, Inc. dba Nofeel
552 Hamilton Street
Suite E-1
Costa Mesa
,
CA
92627
United States
Issuing Office:
Center for Food Safety and Applied Nutrition
5001 Campus Drive
College Park
,
MD
20740
United States
September 11, 2018
Dear Mr. Nersten:
The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter # 543456, issued January 11, 2018. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Carrie Lawlor Branch Chief
Dietary Supplement and Labeling Assessment Branch
Division of Enforcement Office of Compliance
Center for Food Safety and Applied Nutrition
Content current as of:
10/15/2018
Regulated Product(s)
Drugs